CD155-based chimeric antigen receptor T cells: a promising immunotherapy for cervical and breast cancer.

ABSTRACT:

Introduction

As an immune checkpoint molecule that is overexpressed in cervical and breast cancer, CD155 represents an attractive target for chimeric antigen receptor (CAR) T-cell therapy. However, it is crucial to thoroughly assess the efficacy and safety of CD155-based CAR T cells in preclinical models before considering clinical translation.

Methods

In this study, we developed a CD155-based CAR comprising the extracellular domain of the human TIGIT, 4-1BB, and CD3z signaling domains and utilized a murine model of cervical and breast cancer to comprehensively evaluate the antitumor responses elicited by the CD155-based CAR T cells. The CAR construct was specifically designed to recognize and target CD155-expressing tumor cells.

Results

The results of our study indic

SUBMITTER: Ma J 

PROVIDER: S-EPMC12696411 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature